Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod + aipalolitovorelizumab + nab-paclitaxel/carboplatin as neoadjuvant therapy in high-risk early triple-negative breast cancer
ChiCTR2500112788Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Nov 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imiquimod, iparomlimab + tuvonralimab, paclitaxel and carboplatin in triple-negative breast cancer (TNBC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Pathological complete response (pCR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
imiquimodiparomlimab + tuvonralimabpaclitaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2500112788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112788.